RHN 001
Alternative Names: RHN-001Latest Information Update: 31 May 2023
At a glance
- Originator RH Nanopharmaceuticals
- Class Anti-inflammatories; Salicylates; Small molecules
- Mechanism of Action I-kappa B kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Haemophilic arthropathy; Osteoarthritis
Most Recent Events
- 12 May 2023 RH Nanopharmaceuticals has an abandoned patent application for controlled release formulations of saliclate-releasing actives in world .
- 11 May 2023 RHN 001 is available for licensing as of 11 May 2023. https://www.rhnanopharma.com/BusinessDevelopment.html
- 19 Mar 2023 RH Nanopharmaceuticals completes a phase I trial in Osteoarthritis and Haemophilic arthropathy (In volunteers) in Pakistan (PO) (NCT05847218)